A1 Refereed original research article in a scientific journal
Responses to an acellular pertussis booster vaccination in children, adolescents, and young and older adults: A collaborative study in Finland, the Netherlands, and the United Kingdom
Authors: Versteegen Pauline, Valente Pinto Marta, Barkoff Alex M., van Gageldonk Pieter G.M., Kassteele Jan.v.d., van Houten Marlies A., Sanders Elisabeth A.M., de Groot Ronald, Diavatopoulos Dimitri A., Bibi Sagida, Luoto Raakel, He Qiushui, Buisman Anne-Marie, Kelly Dominic F., Mertsola Jussi, Berbers Guy A.M.
Publisher: Elsevier B.V.
Publication year: 2021
Journal: EBioMedicine
Journal name in source: EBioMedicine
Volume: 65
Number of pages: 12
ISSN: 2352-3964
eISSN: 2352-3964
DOI: https://doi.org/10.1016/j.ebiom.2021.103247
Self-archived copy’s web address: https://research.utu.fi/converis/portal/detail/Publication/53634305
Background: Pertussis can lead to serious disease and even death in infants. Older adults are more vulnerable to complications as well. In high-income countries, acellular pertussis vaccines are used for priming vaccination. In the administration of booster vaccinations to different age groups and target populations there is a substantial between-country variation. We investigated the effect of age on the response to acellular pertussis booster vaccination in three European countries.
Methods: This phase IV longitudinal intervention study performed in Finland, the Netherlands and the United Kingdom between October 2017 and January 2019 compared the vaccine responses between healthy participants of four age groups: children (7-10y), adolescents (11-15y), young adults (20-34y), and older adults (60-70y). All participants received a three-component acellular pertussis vaccine. Serum IgG and IgA antibody concentrations to pertussis antigens at day 0, 28, and 1 year were measured with a multiplex immunoassay, using pertussis toxin concentrations at day 28 as primary outcome. This trial is registered with ClinicalTrialsRegister.eu (2016-003,678-42).
Findings: Children (n = 109), adolescents (n = 121), young adults (n = 74), and older adults (n = 75) showed high IgG antibody concentrations to pertussis toxin at day 28 with GMCs of 147 (95% CI 120-181), 161 (95% CI 132-196), 103 (95% CI 80-133), and 121 IU/ml (95% CI 94-155), respectively. A significant increase in GMCs for vaccine antigens in all age groups by 28 days was found which had decreased by 1 year. Differences in patterns of IgG GMCs at 28 days and 1 year post-vaccination did not have a consistent relationship to age. In contrast, IgA antibodies for all antigens increased with age at all timepoints.
Interpretation: Acellular pertussis booster vaccination induces significant serum IgG responses to pertussis antigens across the age range which are not uniformly less in older adults. Acellular boosters could be considered for older adults to reduce the health and economic burden of pertussis.
Downloadable publication This is an electronic reprint of the original article. |  |
